Author

Sélidji Todagbé Agnandji

Observed names: Agnandji, Selidji T, Agnandji, Selidji T., Agnandji, Selidji Todagbe, S. T. Agnandji, S.T. Agnandji, SELIDJI T. AGNANDJI, Selidji Agnandji, Selidji T Agnandji, Selidji T. Agnandji, Selidji Todagbe Agnandji, Selidji Todagbé Agnandji, Selidji T. Agnandji, Selidji T. M. Agnandji

Institutions: University of Münster, Centre de Recherche Médicales de Lambaréné, University Hospital Münster, German Center for Infection Research, University of Tübingen

ORCID: 0000-0003-4693-4207

Observed ORCID: 0000-0003-4693-4207

OpenAlex ID: A5088720377

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.

2015 · Emmanuel B. Bache, Sélidji Todagbé Agnandji, et al. · The Lancet · 642

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

2015 · Daniel E. Neafsey, Michal Juraska, et al. · New England Journal of Medicine · 422

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

2015 · Selidji T. Agnandji, Angela Huttner, et al. · New England Journal of Medicine · 415

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

2015 · Michael T White, Robert Verity, et al. · The Lancet Infectious Diseases · 355

Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy

2019 · Carlota Dobaño, Hèctor Sanz, et al. · Nature Communications · 145

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

2011 · Kwaku Poku Asante, Salim Abdulla, et al. · The Lancet Infectious Diseases · 136

Placental Malaria Increases Malaria Risk in the First 30 Months of Life

2008 · Norbert G. Schwarz, Ayola A. Adegnika, et al. · Clinical Infectious Diseases · 133

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV

2017 · Anne Rechtien, Laura Richert, et al. · Cell Reports · 124

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data

2013 · Philip Bejon, Michael T White, et al. · The Lancet Infectious Diseases · 114

Microscopic and Sub-microscopic Plasmodium Falciparum Infection, but Not Inflammation Caused by Infection, Is Associated With Low Birth Weight

2006 · AYÔLA A. ADEGNIKA, JACO J. VERWEIJ, et al. · American Journal of Tropical Medicine and Hygiene · 113

Epidemiology of parasitic co-infections during pregnancy in Lambaréné, Gabon

2010 · Ayôla A. Adegnika, Michael Ramharter, et al. · Tropical Medicine & International Health · 96

Willingness to Know the Cause of Death and Hypothetical Acceptability of the Minimally Invasive Autopsy in Six Diverse African and Asian Settings: A Mixed Methods Socio-Behavioural Study

2016 · Maria Maixenchs, Rui Anselmo, et al. · PLoS Medicine · 94

Intermittent Preventive Treatment against Malaria in Infants in Gabon—A Randomized, Double‐Blind, Placebo‐Controlled Trial

2007 · Martin P. Grobusch, Bertrand Lell, et al. · The Journal of Infectious Diseases · 94

A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine

2014 · Michael T White, Philip Bejon, et al. · BMC Medicine · 92

Randomized, Controlled, Assessor-Blind Clinical Trial To Assess the Efficacy of Single- versus Repeated-Dose Albendazole To Treat Ascaris lumbricoides, Trichuris trichiura, and Hookworm Infection

2014 · Ayola A. Adegnika, Jeannot F. Zinsou, et al. · Antimicrobial Agents and Chemotherapy · 92

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

2009 · Bertrand Lell, Selidji Agnandji, et al. · PLoS ONE · 88

Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children

2018 · Itziar Ubillos, Aintzane Ayestaran, et al. · BMC Medicine · 87

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

2018 · Angela Huttner, Selidji Todagbe Agnandji, et al. · The Lancet Infectious Diseases · 82

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization

2017 · Christine Dahlke, Rahel Kasonta, et al. · EBioMedicine · 78

Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic

2020 · Jigang Wang, Chengchao Xu, et al. · The Lancet · 75

Evaluation of the Safety and Immunogenicity of the RTS,S/AS01EMalaria Candidate Vaccine When Integrated in the Expanded Program of Immunization

2010 · Selidji T. Agnandji, Kwaku Poku Asante, et al. · The Journal of Infectious Diseases · 73

Burden of disease in Gabon caused by loiasis: a cross-sectional survey

2020 · Luzia Veletzky, Jennifer Hergeth, et al. · The Lancet Infectious Diseases · 72

Urogenital schistosomiasis during pregnancy is associated with low birth weight delivery: analysis of a prospective cohort of pregnant women and their offspring in Gabon

2016 · Ghyslain Mombo-Ngoma, Josiane Honkpehedji, et al. · International Journal for Parasitology · 70

Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa

2019 · Yolanda Guerra Mendoza, Elodie Garric, et al. · Human Vaccines & Immunotherapeutics · 69

Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countries

2017 · Chris Drakeley, Salim Abdulla, et al. · Malaria Journal · 68

Works count: 188

Citation count: 6,632

H-index: 42

I10-index: 119